Mutual exacerbation of peroxisome proliferator-activated receptor γ coactivator 1α deregulation and α-synuclein oligomerization

Annals of Neurology

Volumn 77, Issue 1, 2015, Pages 15-32

  Eschbach, Judith ^a,b   Von Einem, Björn ^a   Müller, Kathrin ^a   Bayer, Hanna ^a   Scheffold, Annika ^a   Morrison, Bradley E ^c   Rudolph, K Lenhard ^d   Thal, Dietmar R ^a   Witting, Anke ^a   Weydt, Patrick ^a   Otto, Markus ^a   Fauler, Michael ^a   Liss, Birgit ^a   McLean, Pamela J ^e   La Spada, Albert R ^c   Ludolph, Albert C ^a   Weishaupt, Jochen H ^a   Danzer, Karin M ^a  

^a UNIVERSITY OF ULM   (Germany)

^b Inoviem Scientific   (France)

^c UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

^d FRITZ LIPMANN INSTITUTE   (Germany)

^e MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

5 AMINO 4 IMIDAZOLECARBOXAMIDE RIBOSIDE; ALPHA SYNUCLEIN; OLIGOMER; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA COACTIVATOR 1ALPHA; RESVERATROL; BAFILOMYCIN A1; ENZYME INHIBITOR; MACROLIDE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PPARGC1A PROTEIN, MOUSE; RNA POLYMERASE II; STILBENE DERIVATIVE; TATA BINDING PROTEIN; TRANSCRIPTION FACTOR;

ADENO ASSOCIATED VIRUS; ADULT; AGED; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; AUTOPHAGY; BRAIN CELL; BRAIN STEM; CELL CULTURE; CELL VIABILITY; CENTRAL NERVOUS SYSTEM; CLINICAL ARTICLE; CONTROLLED STUDY; DOWN REGULATION; FEMALE; GENE OVEREXPRESSION; GENE REPRESSION; GENE SILENCING; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MALE; MESENCEPHALON; MIDDLE AGED; MOUSE; NERVE CELL; NEUROLOGIC DISEASE; NONHUMAN; OLIGOMERIZATION; PARKINSON DISEASE; PRIORITY JOURNAL; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; SPINAL CORD; SYNUCLEINOPATHY; UPREGULATION; VERY ELDERLY; WESTERN BLOTTING; ANIMAL; BRAIN CORTEX; CYTOLOGY; DISEASE MODEL; DRUG EFFECTS; GENE EXPRESSION REGULATION; GENETICS; GLIOMA; MAMMALIAN EMBRYO; METABOLISM; PATHOLOGY; SUBSTANTIA NIGRA; TRANSGENIC MOUSE;

AGED; AGED, 80 AND OVER; ALPHA-SYNUCLEIN; ANIMALS; CELLS, CULTURED; CEREBRAL CORTEX; DISEASE MODELS, ANIMAL; EMBRYO, MAMMALIAN; ENZYME INHIBITORS; FEMALE; GENE EXPRESSION REGULATION; GLIOMA; HUMANS; MACROLIDES; MALE; MICE; MICE, TRANSGENIC; MIDDLE AGED; NEURONS; PARKINSON DISEASE; PPAR GAMMA; RNA POLYMERASE II; STILBENES; SUBSTANTIA NIGRA; TATA-BOX BINDING PROTEIN; TRANSCRIPTION FACTORS;

EID: 84920920653     PISSN: 03645134     EISSN: 15318249     Source Type: Journal    
DOI: 10.1002/ana.24294     Document Type: Article

References (99)

1. Braak H, Del Tredici K, Rub U, et al. Staging of brain pathology related to sporadic Parkinson's disease. Neurobiol Aging 2003;24:197-211.
2. Goedert M. Alpha-synuclein and neurodegenerative diseases. Nat Rev Neurosci 2001;2:492-501.
3. El-Agnaf OM, Salem SA, Paleologou KE, et al. Detection of oligomeric forms of alpha-synuclein protein in human plasma as a potential biomarker for Parkinson's disease. FASEB J 2006;20:419-425.
4. Gosavi N, Lee HJ, Lee JS, et al. Golgi fragmentation occurs in the cells with prefibrillar alpha-synuclein aggregates and precedes the formation of fibrillar inclusion. J Biol Chem 2002;277:48984-48992.
5. Kayed R, Head E, Thompson JL, et al. Common structure of soluble amyloid oligomers implies common mechanism of pathogenesis. Science 2003;300:486-489.
6. Lashuel HA, Hartley D, Petre BM, et al. Neurodegenerative disease: amyloid pores from pathogenic mutations. Nature 2002;418:291.
7. Masliah E, Rockenstein E, Veinbergs I, et al. Dopaminergic loss and inclusion body formation in alpha-synuclein mice: implications for neurodegenerative disorders. Science 2000;287:1265-1269.
8. Danzer KM, Haasen D, Karow AR, et al. Different species of alpha-synuclein oligomers induce calcium influx and seeding. J Neurosci 2007;27:9220-9232.
9. Winner B, Jappelli R, Maji SK, et al. In vivo demonstration that alpha-synuclein oligomers are toxic. Proc Natl Acad Sci U S A 2011;108:4194-4199.
10. Auluck PK, Chan HY, Trojanowski JQ, et al. Chaperone suppression of alpha-synuclein toxicity in a Drosophila model for Parkinson's disease. Science 2002;295:865-868.
11. Bodner RA, Outeiro TF, Altmann S, et al. Pharmacological promotion of inclusion formation: a therapeutic approach for Huntington's and Parkinson's diseases. Proc Natl Acad Sci U S A 2006; 103:4246-4251.
12. Bucciantini M, Calloni G, Chiti F, et al. Prefibrillar amyloid protein aggregates share common features of cytotoxicity. J Biol Chem 2004;279:31374-31382.
13. Park JY, Lansbury PT Jr. Beta-synuclein inhibits formation of alpha-synuclein protofibrils: a possible therapeutic strategy against Parkinson's disease. Biochemistry 2003;42:3696-3700.
14. Abou-Sleiman PM, Muqit MM, Wood NW. Expanding insights of mitochondrial dysfunction in Parkinson's disease. Nat Rev Neurosci 2006;7:207-219.
15. Banerjee R, Starkov AA, Beal MF, Thomas B. Mitochondrial dysfunction in the limelight of Parkinson's disease pathogenesis. Biochim Biophys Acta 2009;1792:651-663.
16. Esteves AR, Arduino DM, Swerdlow RH, et al. Oxidative stress involvement in alpha-synuclein oligomerization in Parkinson's disease cybrids. Antioxid Redox Signal 2009;11:439-448.
17. Zhou C, Huang Y, Przedborski S. Oxidative stress in Parkinson's disease: a mechanism of pathogenic and therapeutic significance. Ann N Y Acad Sci 2008;1147:93-104.
18. Schapira AH, Cooper JM, Dexter D, et al. Mitochondrial complex I deficiency in Parkinson's disease. J Neurochem 1990;54:823-827.
19. Spillantini MG, Schmidt ML, Lee VM, et al. Alpha-synuclein in Lewy bodies. Nature 1997;388:839-840.
20. Lin MT, Beal MF. Mitochondrial dysfunction and oxidative stress in neurodegenerative diseases. Nature 2006;443:787-795.
21. Betarbet R, Sherer TB, MacKenzie G, et al. Chronic systemic pesticide exposure reproduces features of Parkinson's disease. Nat Neurosci 2000;3:1301-1306.
22. Langston JW, Ballard PA Jr. Parkinson's disease in a chemist working with 1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine. N Engl J Med 1983;309:310.
23. Sherer TB, Betarbet R, Kim JH, Greenamyre JT. Selective microglial activation in the rat rotenone model of Parkinson's disease. Neurosci Lett 2003;341:87-90.
24. Zhang D, Anantharam V, Kanthasamy A, Kanthasamy AG. Neuroprotective effect of protein kinase C delta inhibitor rottlerin in cell culture and animal models of Parkinson's disease. J Pharmacol Exp Ther 2007;322:913-922.
25. Betarbet R, Canet-Aviles RM, Sherer TB, et al. Intersecting pathways to neurodegeneration in Parkinson's disease: effects of the pesticide rotenone on DJ-1, alpha-synuclein, and the ubiquitin-proteasome system. Neurobiol Dis 2006;22:404-420.
26. Schapira AH. Mitochondria in the aetiology and pathogenesis of Parkinson's disease. Lancet Neurol 2008;7:97-109.
27. Sherer TB, Betarbet R, Stout AK, et al. An in vitro model of Parkinson's disease: linking mitochondrial impairment to altered alpha-synuclein metabolism and oxidative damage. J Neurosci 2002;22:7006-7015.
28. Thomas B, Beal MF. Parkinson's disease. Hum Mol Genet 2007;16 Spec No. 2:R183-R194.
29. Puigserver P, Spiegelman BM. Peroxisome proliferator-activated receptor-gamma coactivator 1 alpha (PGC-1 alpha): transcriptional coactivator and metabolic regulator. Endocr Rev 2003;24:78-90.
30. St-Pierre J, Drori S, Uldry M, et al. Suppression of reactive oxygen species and neurodegeneration by the PGC-1 transcriptional coactivators. Cell 2006;127:397-408.
31. Tsunemi T, Ashe TD, Morrison BE, et al. PGC-1alpha rescues Huntington's disease proteotoxicity by preventing oxidative stress and promoting TFEB function. Sci Transl Med 2012;4:142ra97.
32. Ruas JL, White JP, Rao RR, et al. A PGC-1alpha isoform induced by resistance training regulates skeletal muscle hypertrophy. Cell 2012;151:1319-1331.
33. Soyal SM, Felder TK, Auer S, et al. A greatly extended PPARGC1A genomic locus encodes several new brain-specific isoforms and influences Huntington disease age of onset. Hum Mol Genet 2012;21:3461-3473.
34. Rona-Voros K, Weydt P. The role of PGC-1α in the pathogenesis of neurodegenerative disorders. Curr Drug Targets 2010;11:1262-1269.
35. Che HV, Metzger S, Portal E, et al. Localization of sequence variations in PGC-1alpha influence their modifying effect in Huntington disease. Mol Neurodegener 2011;6:1.
36. Taherzadeh-Fard E, Saft C, Andrich J, et al. PGC-1alpha as modifier of onset age in Huntington disease. Mol Neurodegener 2009;4:10.
37. Weydt P, Soyal SM, Gellera C, et al. The gene coding for PGC-1alpha modifies age at onset in Huntington's Disease. Mol Neurodegener 2009;4:3.
38. Weydt P, Soyal SM, Landwehrmeyer GB, Patsch W. A single nucleotide polymorphism in the coding region of PGC-1alpha is a male-specific modifier of Huntington disease age-at-onset in a large European cohort. BMC Neurol 2014;14:1.
39. Ramos EM, Latourelle JC, Lee JH, et al. Population stratification may bias analysis of PGC-1alpha as a modifier of age at Huntington disease motor onset. Hum Genet 2012;131:1833-1840.
40. Zhao W, Varghese M, Yemul S, et al. Peroxisome proliferator activator receptor gamma coactivator-1alpha (PGC-1alpha) improves motor performance and survival in a mouse model of amyotrophic lateral sclerosis. Mol Neurodegener 2011;6:51.
41. Liang H, Ward WF, Jang YC, et al. PGC-1alpha protects neurons and alters disease progression in an amyotrophic lateral sclerosis mouse model. Muscle Nerve 2011;44:947-956.
42. Eschbach J, Schwalenstocker B, Soyal SM, et al. PGC-1alpha is a male-specific disease modifier of human and experimental amyotrophic lateral sclerosis. Hum Mol Genet 2013;22:3477-3484.
43. Zheng B, Liao Z, Locascio JJ, et al. PGC-1alpha, a potential therapeutic target for early intervention in Parkinson's disease. Sci Transl Med 2010;2:52ra73.
44. Ciron C, Lengacher S, Dusonchet J, et al. Sustained expression of PGC-1alpha in the rat nigrostriatal system selectively impairs dopaminergic function. Hum Mol Genet 2012;21:1861-1876.
45. Shin JH, Ko HS, Kang H, et al. PARIS (ZNF746) repression of PGC-1alpha contributes to neurodegeneration in Parkinson's disease. Cell 2011;144:689-702.
46. Siddiqui A, Chinta SJ, Mallajosyula JK, et al. Selective binding of nuclear alpha-synuclein to the PGC1alpha promoter under conditions of oxidative stress may contribute to losses in mitochondrial function: implications for Parkinson's disease. Free Radic Biol Med 2012;53:993-1003.
47. Wareski P, Vaarmann A, Choubey V, et al. PGC-1{alpha} and PGC-1{beta} regulate mitochondrial density in neurons. J Biol Chem 2009;284:21379-21385.
48. Kahle PJ, Neumann M, Ozmen L, Haass C. Physiology and pathophysiology of alpha-synuclein. Cell culture and transgenic animal models based on a Parkinson's disease-associated protein. Ann N Y Acad Sci 2000;920:33-41.
49. Neumann M, Kahle PJ, Giasson BI, et al. Misfolded proteinase K-resistant hyperphosphorylated alpha-synuclein in aged transgenic mice with locomotor deterioration and in human alpha-synucleinopathies. J Clin Invest 2002;110:1429-1439.
50. Gomez-Isla T, Irizarry MC, Mariash A, et al. Motor dysfunction and gliosis with preserved dopaminergic markers in human alpha-synuclein A30P transgenic mice. Neurobiol Aging 2003;24:245-258.
51. Yavich L, Oksman M, Tanila H, et al. Locomotor activity and evoked dopamine release are reduced in mice overexpressing A30P-mutated human alpha-synuclein. Neurobiol Dis 2005;20:303-313.
52. Leone TC, Lehman JJ, Finck BN, et al. PGC-1alpha deficiency causes multi-system energy metabolic derangements: muscle dysfunction, abnormal weight control and hepatic steatosis. PLoS Biol 2005;3:e101.
53. Danzer KM, Ruf WP, Putcha P, et al. Heat-shock protein 70 modulates toxic extracellular alpha-synuclein oligomers and rescues trans-synaptic toxicity. FASEB J 2011;25:326-336.
54. Danzer KM, Kranich LR, Ruf WP, et al. Exosomal cell-to-cell transmission of alpha synuclein oligomers. Mol Neurodegener 2012;7:42.
55. Weydt P, Pineda VV, Torrence AE, et al. Thermoregulatory and metabolic defects in Huntington's disease transgenic mice implicate PGC-1alpha in Huntington's disease neurodegeneration. Cell Metab 2006;4:349-362.
56. Braunstein KE, Eschbach J, Rona-Voros K, et al. A point mutation in the dynein heavy chain gene leads to striatal atrophy and compromises neurite outgrowth of striatal neurons. Hum Mol Genet 2010;19:4385-4398.
57. Eschbach J, Fergani A, Oudart H, et al. Mutations in cytoplasmic dynein lead to a Huntington's disease-like defect in energy metabolism of brown and white adipose tissues. Biochim Biophys Acta 2011;1812:59-69.
58. Schlaudraff F, Grundemann J, Fauler M, et al. Orchestrated increase of dopamine and PARK mRNAs but not miR-133b in dopamine neurons in Parkinson's disease. Neurobiol Aging 2014;35:2302-2315.
59. Rogers CE. Symbolic description of factorial models for analysis of variance. J R Stat Soc 1973;22:392-399.
60. Fassina L, Magenes G, Inzaghi A, et al. AUTOCOUNTER, an ImageJ JavaScript to analyze LC3B-GFP expression dynamics in autophagy-induced astrocytoma cells. Eur J Histochem 2012;56:e44.
61. Freichel C, Neumann M, Ballard T, et al. Age-dependent cognitive decline and amygdala pathology in alpha-synuclein transgenic mice. Neurobiol Aging 2007;28:1421-1435.
62. Outeiro TF, Putcha P, Tetzlaff JE, et al. Formation of toxic oligomeric alpha-synuclein species in living cells. PLoS One 2008;3:e1867.
63. Putcha P, Danzer KM, Kranich LR, et al. Brain-permeable small-molecule inhibitors of Hsp90 prevent alpha-synuclein oligomer formation and rescue alpha-synuclein-induced toxicity. J Pharmacol Exp Ther 2010;332:849-857.
64. Remy I, Michnick SW. A highly sensitive protein-protein interaction assay based on Gaussia luciferase. Nat Methods 2006;3:977-979.
65. Lagouge M, Argmann C, Gerhart-Hines Z, et al. Resveratrol improves mitochondrial function and protects against metabolic disease by activating SIRT1 and PGC-1alpha. Cell 2006;127:1109-1122.
66. Tadaishi M, Miura S, Kai Y, et al. Effect of exercise intensity and AICAR on isoform-specific expressions of murine skeletal muscle PGC-1alpha mRNA: a role of beta(2)-adrenergic receptor activation. Am J Physiol Endocrinol Metab 2011;300:E341-E349.
67. Price NL, Gomes AP, Ling AJ, et al. SIRT1 is required for AMPK activation and the beneficial effects of resveratrol on mitochondrial function. Cell Metab 2012;15:675-690.
68. Dasgupta B, Milbrandt J. Resveratrol stimulates AMP kinase activity in neurons. Proc Natl Acad Sci U S A 2007;104:7217-7222.
69. Jager S, Handschin C, St-Pierre J, Spiegelman BM. AMP-activated protein kinase (AMPK) action in skeletal muscle via direct phosphorylation of PGC-1alpha. Proc Natl Acad Sci U S A 2007;104:12017-12022.
70. Canto C, Gerhart-Hines Z, Feige JN, et al. AMPK regulates energy expenditure by modulating NAD+ metabolism and SIRT1 activity. Nature 2009;458:1056-1060.
71. Bain J, Plater L, Elliott M, et al. The selectivity of protein kinase inhibitors: a further update. Biochem J 2007;408:297-315.
72. Desplats P, Lee HJ, Bae EJ, et al. Inclusion formation and neuronal cell death through neuron-to-neuron transmission of alpha-synuclein. Proc Natl Acad Sci U S A 2009;106:13010-13015.
73. Danzer KM, Krebs SK, Wolff M, et al. Seeding induced by alpha-synuclein oligomers provides evidence for spreading of alpha-synuclein pathology. J Neurochem 2009;111:192-203.
74. Luk KC, Song C, O'Brien P, et al. Exogenous alpha-synuclein fibrils seed the formation of Lewy body-like intracellular inclusions in cultured cells. Proc Natl Acad Sci U S A 2009;106:20051-20056.
75. Luk KC, Kehm V, Carroll J, et al. Pathological alpha-synuclein transmission initiates Parkinson-like neurodegeneration in nontransgenic mice. Science 2012;338:949-953.
76. Luk KC, Kehm VM, Zhang B, et al. Intracerebral inoculation of pathological alpha-synuclein initiates a rapidly progressive neurodegenerative alpha-synucleinopathy in mice. J Exp Med 2012;209:975-986.
77. Hansen C, Angot E, Bergstrom AL, et al. α-Synuclein propagates from mouse brain to grafted dopaminergic neurons and seeds aggregation in cultured human cells. J Clin Invest 2011;121:715-725.
78. Tritos NA, Mastaitis JW, Kokkotou EG, et al. Characterization of the peroxisome proliferator activated receptor coactivator 1 alpha (PGC 1alpha) expression in the murine brain. Brain Res 2003;961:255-260.
79. Lehman JJ, Barger PM, Kovacs A, et al. Peroxisome proliferator-activated receptor gamma coactivator-1 promotes cardiac mitochondrial biogenesis. J Clin Invest 2000;106:847-856.
80. Russell LK, Mansfield CM, Lehman JJ, et al. Cardiac-specific induction of the transcriptional coactivator peroxisome proliferator-activated receptor gamma coactivator-1alpha promotes mitochondrial biogenesis and reversible cardiomyopathy in a developmental stage-dependent manner. Circ Res 2004;94:525-533.
81. Miura S, Tomitsuka E, Kamei Y, et al. Overexpression of peroxisome proliferator-activated receptor gamma co-activator-1alpha leads to muscle atrophy with depletion of ATP. Am J Pathol 2006;169:1129-1139.
82. Bonen A. PGC-1alpha-induced improvements in skeletal muscle metabolism and insulin sensitivity. Appl Physiol Nutr Metab 2009;34:307-314.
83. Rathke-Hartlieb S, Kahle PJ, Neumann M, et al. Sensitivity to MPTP is not increased in Parkinson's disease-associated mutant alpha-synuclein transgenic mice. J Neurochem 2001;77:1181-1184.
84. Chaturvedi RK, Adhihetty P, Shukla S, et al. Impaired PGC-1alpha function in muscle in Huntington's disease. Hum Mol Genet 2009;18:3048-3065.
85. Chaturvedi RK, Calingasan NY, Yang L, et al. Impairment of PGC-1alpha expression, neuropathology and hepatic steatosis in a transgenic mouse model of Huntington's disease following chronic energy deprivation. Hum Mol Genet 2010;19:3190-3205.
86. Cui L, Jeong H, Borovecki F, et al. Transcriptional repression of PGC-1alpha by mutant huntingtin leads to mitochondrial dysfunction and neurodegeneration. Cell 2006;127:59-69.
87. Johri A, Chandra A, Beal MF. PGC-1alpha, mitochondrial dysfunction, and Huntington's disease. Free Radic Biol Med 2013;62:37-46.
88. Chiang MC, Chen CM, Lee MR, et al. Modulation of energy deficiency in Huntington's disease via activation of the peroxisome proliferator-activated receptor gamma. Hum Mol Genet 2010;19:4043-4058.
89. Ho DJ, Calingasan NY, Wille E, et al. Resveratrol protects against peripheral deficits in a mouse model of Huntington's disease. Exp Neurol 2010;225:74-84.
90. Johri A, Calingasan NY, Hennessey TM, et al. Pharmacologic activation of mitochondrial biogenesis exerts widespread beneficial effects in a transgenic mouse model of Huntington's disease. Hum Mol Genet 2012;21:1124-1137.
91. Licker V, Turck N, Kovari E, et al. Proteomic analysis of human substantia nigra identifies novel candidates involved in Parkinson's disease pathogenesis. Proteomics 2014;14:784-794.
92. Panov A, Dikalov S, Shalbuyeva N, et al. Rotenone model of Parkinson disease: multiple brain mitochondria dysfunctions after short term systemic rotenone intoxication. J Biol Chem 2005;280:42026-42035.
93. Pienaar IS, Elson JL, Racca C, et al. Mitochondrial abnormality associates with type-specific neuronal loss and cell morphology changes in the pedunculopontine nucleus in Parkinson disease. Am J Pathol 2013;183:1826-1840.
94. Przedborski S, Tieu K, Perier C, Vila M. MPTP as a mitochondrial neurotoxic model of Parkinson's disease. J Bioenerg Biomembr 2004;36:375-379.
95. Tufi R, Gandhi S, de Castro IP, et al. Enhancing nucleotide metabolism protects against mitochondrial dysfunction and neurodegeneration in a PINK1 model of Parkinson's disease. Nat Cell Biol 2014;16:157-166.
96. Mudo G, Makela J, Di Liberto V, et al. Transgenic expression and activation of PGC-1alpha protect dopaminergic neurons in the MPTP mouse model of Parkinson's disease. Cell Mol Life Sci 2012;69:1153-1165.
97. Hsu LJ, Sagara Y, Arroyo A, et al. alpha-synuclein promotes mitochondrial deficit and oxidative stress. Am J Pathol 2000;157:401-410.
98. Ono K, Yamada M. Antioxidant compounds have potent anti-fibrillogenic and fibril-destabilizing effects for alpha-synuclein fibrils in vitro. J Neurochem 2006;97:105-115.
99. Decressac M, Mattsson B, Weikop P, et al. TFEB-mediated autophagy rescues midbrain dopamine neurons from alpha-synuclein toxicity. Proc Natl Acad Sci U S A 2013;110:E1817-E1826.